Lanark Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 08-12-2024
- Paid Up Capital ₹ 0.20 M
as on 08-12-2024
- Company Age 23 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 73.07%
(FY 2022)
- Profit 206.87%
(FY 2022)
- Ebitda 195.28%
(FY 2022)
- Net Worth 11.54%
(FY 2022)
- Total Assets -24.15%
(FY 2022)
About Lanark Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Rajeev Mukul, Dinesh Kakar, and Anil Mehta serve as directors at the Company.
- CIN/LLPIN
U24232DL2001PTC111048
- Company No.
111048
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 May 2001
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- LocationNa, Delhi
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Lanark Laboratories Pvt Ltd offer?
Lanark Laboratories Pvt Ltd offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets, Multivitamin Tablets & Capsules, Iron Folic Acid Tablet, Antioxidant Capsule.
Who are the key members and board of directors at Lanark Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeev Mukul  | Director | 01-Aug-2010 | Current |
| Dinesh Kakar | Director | 01-Jul-2003 | Current |
| Anil Mehta | Director | 11-Jun-2015 | Current |
Financial Performance of Lanark Laboratories.
Lanark Laboratories Pvt Ltd, for the financial year ended 2022, experienced significant growth in revenue, with a 73.07% increase. The company also saw a substantial improvement in profitability, with a 206.87% increase in profit. The company's net worth Soared by an impressive increase of 11.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lanark Laboratories?
In 2022, Lanark Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Deventure Hotels Private LimitedActive 16 years 6 monthsRajeev Mukul and Dinesh Kakar are mutual person
- Klokter Life Sciences Private LimitedActive 5 years 2 months
Rajeev Mukul and Dinesh Kakar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lanark Laboratories?
Unlock and access historical data on people associated with Lanark Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lanark Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lanark Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
